A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety oF MORAb-003(Farletuzumab)in Combination With Paclitaxel Therapy in Subjects With Platinum-Resistant or Refractory Relapsed Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Farletuzumab (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Morphotek
- 05 May 2015 Protocol has been amended in change of phase of the study from III to II.
- 19 Apr 2012 Actual patient number 417 added as reported by ClinicalTrials.gov.
- 05 Dec 2011 Status changed from recruiting to discontinued.